Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Inst
- PDF / 796,485 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 100 Downloads / 192 Views
ORIGINAL RESEARCH ARTICLE
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi‑Institutional Analysis Roberto Iacovelli1 · Chiara Ciccarese1,2 · Gaetano Facchini3 · Michele Milella4 · Federica Urbano5 · Umberto Basso6 · Ugo De Giorgi7 · Roberto Sabbatini8 · Daniele Santini9 · Rossana Berardi10 · Matteo Santoni11 · Sergio Bracarda12 · Francesco Massari13 · Cristina Masini14 · Michele De Tursi15 · Riccardo Ricotta16 · Sebastiano Buti17 · Fable Zustovich18 · Pierangela Sepe19 · Sabrina Rossetti3 · Marco Maruzzo6 · Enrico Cortesi5 · Giampaolo Tortora1,2 · Giuseppe Procopio19
© Springer Nature Switzerland AG 2020
Abstract Background Angiogenesis has been recognized as the most important factor for tumor invasion, proliferation, and progression in metastatic renal cell carcinoma (mRCC). However, few clinical data are available regarding the efficacy of cabozantinib following immunotherapy. Objective To describe the outcome of cabozantinib in patients previously treated with immunotherapy. Patients and methods Patients with mRCC who received cabozantinib immediately after nivolumab were included. The primary endpoint was to assess the outcome in terms of efficacy and activity. Results Eighty-four mRCC patients met the criteria to be included in the final analysis. After a median follow-up of 9.4 months, median overall survival was 17.3 months. According to the IMDC criteria, the rates of patients alive at 12 months in the good, intermediate, and poor prognostic groups were 100%, 74%, and 33%, respectively (p
Data Loading...
